Did the drug company not fully disclose the potential side effects...and was the less expensive generic doing the job? BD
Here’s more trouble for Schering-Plough. The drugmaker just spent $14.3 billion to buy Organon, which now faces allegations that the number and severity of serious adverse events associated with its troubled neuromuscular blocking agent known as Raplon were not disclosed before or after FDA approval, according to a whistleblower lawsuit filed in federal court in New Jersey.
Pharmalot » Organon Allegedly Covered Up Raplon Side Effects
0 comments :
Post a Comment